Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Shares Purchased by Ritholtz Wealth Management

Ritholtz Wealth Management boosted its holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 7.8% during the 1st quarter, according to the company in its most recent disclosure with the SEC. The fund owned 486 shares of the biopharmaceutical company’s stock after buying an additional 35 shares during the quarter. Ritholtz Wealth Management’s holdings in Regeneron Pharmaceuticals were worth $308,000 as of its most recent SEC filing.

Other hedge funds have also recently added to or reduced their stakes in the company. Pinney & Scofield Inc. acquired a new position in Regeneron Pharmaceuticals in the fourth quarter worth approximately $25,000. Rakuten Securities Inc. grew its position in Regeneron Pharmaceuticals by 62.5% in the fourth quarter. Rakuten Securities Inc. now owns 39 shares of the biopharmaceutical company’s stock worth $28,000 after buying an additional 15 shares during the last quarter. OFI Invest Asset Management acquired a new position in Regeneron Pharmaceuticals in the fourth quarter worth approximately $28,000. Avalon Trust Co acquired a new position in Regeneron Pharmaceuticals in the fourth quarter worth approximately $36,000. Finally, Crowley Wealth Management Inc. acquired a new position in Regeneron Pharmaceuticals in the fourth quarter worth approximately $36,000. Institutional investors and hedge funds own 83.31% of the company’s stock.

Regeneron Pharmaceuticals Trading Down 0.8%

Regeneron Pharmaceuticals stock opened at $509.72 on Friday. The company’s fifty day simple moving average is $558.34 and its 200-day simple moving average is $641.68. The company has a quick ratio of 4.03, a current ratio of 4.93 and a debt-to-equity ratio of 0.09. Regeneron Pharmaceuticals, Inc. has a 12 month low of $476.49 and a 12 month high of $1,211.20. The stock has a market cap of $55.03 billion, a P/E ratio of 12.98, a P/E/G ratio of 1.88 and a beta of 0.31.

Regeneron Pharmaceuticals (NASDAQ:REGN) last released its quarterly earnings data on Tuesday, April 29th. The biopharmaceutical company reported $8.22 earnings per share (EPS) for the quarter, missing the consensus estimate of $8.83 by ($0.61). Regeneron Pharmaceuticals had a net margin of 31.94% and a return on equity of 15.27%. The business had revenue of $3.03 billion during the quarter, compared to analyst estimates of $3.40 billion. During the same period in the previous year, the firm posted $9.55 EPS. The firm’s revenue for the quarter was down 3.7% on a year-over-year basis. As a group, sell-side analysts forecast that Regeneron Pharmaceuticals, Inc. will post 35.92 EPS for the current fiscal year.

Regeneron Pharmaceuticals Announces Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Friday, June 6th. Investors of record on Tuesday, May 20th were paid a $0.88 dividend. This represents a $3.52 annualized dividend and a dividend yield of 0.69%. The ex-dividend date of this dividend was Tuesday, May 20th. Regeneron Pharmaceuticals’s payout ratio is presently 8.96%.

Wall Street Analysts Forecast Growth

Several equities analysts have weighed in on REGN shares. UBS Group lowered their price objective on shares of Regeneron Pharmaceuticals from $633.00 to $560.00 and set a “neutral” rating on the stock in a research report on Thursday, June 5th. Canaccord Genuity Group upgraded shares of Regeneron Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a research report on Tuesday, April 22nd. Bank of America lowered their price objective on shares of Regeneron Pharmaceuticals from $575.00 to $547.00 and set an “underperform” rating on the stock in a research report on Thursday, April 17th. Royal Bank Of Canada cut shares of Regeneron Pharmaceuticals from a “moderate buy” rating to a “hold” rating and set a $662.00 price objective on the stock. in a research report on Friday, May 30th. Finally, Cantor Fitzgerald started coverage on shares of Regeneron Pharmaceuticals in a research report on Tuesday, April 22nd. They set an “overweight” rating and a $695.00 price objective on the stock. One investment analyst has rated the stock with a sell rating, six have issued a hold rating, seventeen have issued a buy rating and three have given a strong buy rating to the company’s stock. Based on data from MarketBeat, Regeneron Pharmaceuticals presently has a consensus rating of “Moderate Buy” and a consensus target price of $836.48.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.